Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMISIA study of nebivolol + ramipril in uncontrolled hypertension
2022-003060-25Phase 4Completed
- Sponsor
- Menarini Group
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nebivolol and ramipril in hypertension (HTN), sponsored by Menarini Group. Primary endpoint: Change in mean sitting diastolic blood pressure. Started Jan 2023; status: completed.
02
Drugs
nebivololramipril
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2022-003060-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003060-25.